Feb 26 (Reuters) - Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.

NNNN

PMCB

SBIO

<p>Feb 26 (Reuters) - Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.</p>

Reuters

Anbio Biotechnology

First Trust NYSE Arca Biotech Index Fd

PharmaCyte Biotech

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Drug developer Generate Biomedicines raises $400 million in US IPO